Market growth is attributed to the increasing cases of infertility in men and women and growing advancements in infertility testing. Growing awareness campaigns will likely provide growth opportunities for the infertility testing market. However, the lack of awareness and limitations associated with infertility testing kits hinder the growth of the hyperbaric oxygen therapy market.
According to a study titled "Fertility and Infertility: Definition and Epidemiology," published in Elsevier B.V., infertility is known to affect around 8-12% of couples across the world. The proportion is gradually increasing due to several causes such as modern lifestyles, illnesses, and the postponement of parenthood. In the male reproductive system, infertility is most often caused by problems ejecting semen, missing or small amounts of sperm, or abnormal shape (morphology) and movement (motility) of sperm. In females, infertility can be caused by abnormalities associated with the uterus, ovaries, fallopian tubes, and endocrine system.
North America accounted for a major share of the global infertility testing market in 2022. The North American infertility testing market is segmented into the US, Canada, and Mexico. The market growth in this region is driven by the high occurrence of infertility, increasing awareness of infertility testing among men and women, the growing female population affected by PCOS, the rising age of first pregnancy among women, and the easy availability of infertility test kits through e-commerce websites. Also, changing lifestyles with increasing trends of unhealthy diets leading to infertility and gynecological disorders in men and women are responsible for the infertility testing market growth. Furthermore, technological advancements in ovulation monitors are bolstering the market growth in the region. Furthermore, the rising consumption of smoking and tobacco will lead to an increase in infertility cases, propelling the market growth. Growing demand for self-testing and remote monitoring testing among women and innovation of new products are expected to create profitable market opportunities.
Growing Awareness Campaigns Fuels the Infertility Testing Market Growth Opportunities
The pregnancy issues among couples have been traditionally blamed on females for being infertile. However, the modern age of human science and in-depth research and studies have led to a shift in the social stigma with a light on infertility among men. Recently, males are being tested and becoming aware of factors responsible for infertility. Although the scenario is improving in some regions of the world, various parts and geographies are still unaware of the availability of new testing and treatment options as well as the condition.
This provides organizations and companies opportunities to hold and organize awareness campaigns that shed light on this sensitive yet important issue faced by a significant percentage of males across the globe. For instance, in November 2020, Nova IVF Fertility in collaboration with the Times of India, initiated a movement called "Fertile Conversations" that hosted social meet-ups and discussions for infertility issues among males and females with experts in the field. In addition, Cooper Genomics, a Cooper Surgical company, launched the National Infertility Awareness Week: Infertility Uncovered campaign to educate the common people regarding the impact of infertility and well-aware patients regarding products and services available with the company to empower families worldwide. Thus, appropriate awareness campaigns are expected to provide robust showcasing platforms for companies, thereby offering growth opportunities to propel revenues within the dynamic ecosystem.
Type -Based Insights
Based on type, the infertility testing market analysis is carried out by considering the following segments: male and female. The female infertility testing segment held a larger market share in 2022. The male infertility testing segment is anticipated to register a higher CAGR of 9.2% during the forecast period.
Declining female fertility rates, increasing prevalence of gynecological issues in women, busier lifestyles of working women leading to more stress, and low egg counts are among the main factors responsible for the high infertility testing market share. Additionally, the availability of many female infertility tests contributes to the market growth for the female infertility testing segment.
Test Kits -Based Insights
By test kits, the infertility testing market is segmented into human follicular stimulating hormone (FSH) test kits, human chorionic gonadotropin (HCG) hormone test kits, luteinizing hormone (LH) test kits, and others. In terms of revenue, the human follicular stimulating hormone (FSH) test kits segment dominated the infertility testing market share in 2022. The highest CAGR of 9.2% is anticipated to be registered during the forecast period.
The follicular stimulating hormone (FSH) test kit helps measure the concentration of FSH hormone in the blood. The test is often used to assess FSH levels in men and women for various reasons such as fertility problems, menopause, or problems with sexual development. In addition, advanced biosimilar FSH products, regulatory approvals, market access, technological advances in FSH kit production, and a growing need for effective contraceptive options are predicted to accelerate global market growth.
End User -Based Insights
The infertility testing market, by end user, is categorized into hospitals & clinics, fertility centers, and homecare. The homecare segment held the largest market share in 2022 and is anticipated to register the highest CAGR of 9.0% during the forecast period.
Leading players are implementing strategies such as expansion, partnership, launch of new products, and acquiring a new customer base to tap prevailing business opportunities.
The US Food and Drug Administration, Centers for Disease Control and Prevention (CDC), and Global Burden of Disease Study are the primary and secondary sources referred to while preparing the infertility testing market report.